Shares of Dynavax Technologies Co. (NASDAQ:DVAX) have received a consensus recommendation of “Hold” from the seven research firms that are presently covering the stock, Marketbeat Ratings reports. Three research analysts have rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $27.67.

A number of equities research analysts have recently weighed in on DVAX shares. BidaskClub raised shares of Dynavax Technologies from a “sell” rating to a “hold” rating in a report on Wednesday, January 16th. ValuEngine lowered shares of Dynavax Technologies from a “hold” rating to a “sell” rating in a report on Monday, February 4th. Cantor Fitzgerald reissued an “overweight” rating and set a $28.00 price objective (down from $32.00) on shares of Dynavax Technologies in a report on Tuesday, February 26th. Finally, Zacks Investment Research lowered shares of Dynavax Technologies from a “hold” rating to a “sell” rating in a report on Monday, March 4th.

In other Dynavax Technologies news, SVP Robert Coffman sold 63,202 shares of the company’s stock in a transaction on Thursday, February 28th. The shares were sold at an average price of $9.03, for a total value of $570,714.06. Following the sale, the senior vice president now directly owns 86,268 shares of the company’s stock, valued at $779,000.04. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Michael S. Ostrach sold 35,444 shares of the company’s stock in a transaction on Thursday, February 28th. The shares were sold at an average price of $8.94, for a total transaction of $316,869.36. Following the completion of the sale, the insider now directly owns 121,581 shares in the company, valued at $1,086,934.14. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 119,411 shares of company stock worth $1,075,091. 3.47% of the stock is owned by corporate insiders.

A number of large investors have recently bought and sold shares of the business. State Board of Administration of Florida Retirement System boosted its holdings in Dynavax Technologies by 4.1% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 25,121 shares of the biopharmaceutical company’s stock valued at $230,000 after purchasing an additional 996 shares during the last quarter. Wall Street Access Asset Management LLC boosted its holdings in Dynavax Technologies by 7.0% in the fourth quarter. Wall Street Access Asset Management LLC now owns 15,300 shares of the biopharmaceutical company’s stock valued at $140,000 after purchasing an additional 1,000 shares during the last quarter. Commonwealth Equity Services LLC boosted its holdings in Dynavax Technologies by 6.5% in the first quarter. Commonwealth Equity Services LLC now owns 23,374 shares of the biopharmaceutical company’s stock valued at $170,000 after purchasing an additional 1,433 shares during the last quarter. Gables Capital Management Inc. boosted its holdings in Dynavax Technologies by 2.1% in the fourth quarter. Gables Capital Management Inc. now owns 81,550 shares of the biopharmaceutical company’s stock valued at $746,000 after purchasing an additional 1,650 shares during the last quarter. Finally, Legal & General Group Plc boosted its holdings in Dynavax Technologies by 18.7% in the fourth quarter. Legal & General Group Plc now owns 11,814 shares of the biopharmaceutical company’s stock valued at $108,000 after purchasing an additional 1,860 shares during the last quarter. 84.07% of the stock is currently owned by institutional investors.

Shares of DVAX stock opened at $6.76 on Friday. The firm has a market cap of $454.80 million, a PE ratio of -2.65 and a beta of 0.60. The company has a debt-to-equity ratio of 4.88, a quick ratio of 4.08 and a current ratio of 5.27. Dynavax Technologies has a 12-month low of $6.22 and a 12-month high of $19.85.

Dynavax Technologies (NASDAQ:DVAX) last announced its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.05. The firm had revenue of $5.77 million for the quarter, compared to analyst estimates of $5.95 million. Dynavax Technologies had a negative net margin of 1,156.11% and a negative return on equity of 190.84%. The business’s quarterly revenue was up 3294.1% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.63) earnings per share. On average, analysts predict that Dynavax Technologies will post -2.21 earnings per share for the current year.

About Dynavax Technologies

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older.

See Also: What are economic reports?

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.